HLB Panagene

HLB파나진 · 046210

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$46.6M (₩64.3B)

Overview

HLB Panagene develops and supplies diagnostic tools and reagents used to detect genetic information, helping medical professionals identify diseases and conditions at the molecular level.

Its products are used in clinical and research settings, placing the company in the life-science diagnostics supply chain. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company currently generates most of its revenue from its molecular diagnostics product lines.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$10.9M

▲ +14.0% YoY

Operating profit · FY2025

−US$2.5M

Loss widened

Net income · FY2025

−US$2.3M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$8.9M(₩12.3B)	US$9.6M(₩13.2B)	US$10.9M(₩15B)
Operating profit	−US$1.3M(−₩1.8B)	−US$986.9K(−₩1.4B)	−US$2.5M(−₩3.4B)
Net income	−US$3.5M(−₩4.8B)	−US$1.5M(−₩2.1B)	−US$2.3M(−₩3.1B)

Revenue

FY2023US$8.9M
FY2024US$9.6M
FY2025US$10.9M

Operating profit

FY2023−US$1.3M
FY2024−US$986.9K
FY2025−US$2.5M

Net income

FY2023−US$3.5M
FY2024−US$1.5M
FY2025−US$2.3M

Key ratios (FY2025)

ROE

-4.3%

Debt/Eq

28.3%

Op. margin

-22.9%

Net margin

-20.8%

Rev. YoY

▲ +14.0%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?